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Twenty-three patients were evaluated from 1-15 (mean 6) years after recover-
ing from an episode of diarrhea-associated childhood hemolytic uremic syn-
drome (DA-HUS). All patients had received only conservative treatment; none
had been given experimental, anti-coagulant, or immunological therapies.
Follow-up studies included morphologic and duplex Doppler sonograms.
Doppler sonography was used to determine the resistive index, a measure of
renovascular resistance. Histories and physical examiniations revealed no
abnormalities. Results of laboratory studies, which included calculated
glomerular filtration rates, were all within normal limits, except for onepatient
with minor urinary abnormalities. Renal sonograms showed no significant
abnormalities ofkidney length or parenchymal appearance. However, Doppler
sonographic examinations revealed that the DA-HUS patients demonstrated
less of adecrease inrenovascularresistance with age than did the control group
(p<0.0002). After recovery, patients treated exclusively with conservative man-
agement during an acute episode of DA-HUS appeared to have an excellent
long-term prognosis. Comparison ofourresults with thosefromotherstudies in
which investigational therapies have been used during the acute phase of DA-
HUS suggests that latent toxicities which cause long term sequelae may not
have been appreciated previously. The clinical significance of the altered renal
vascularresistance remains to bedelineated.
INTRODUCTION
HUS' is defined by the acute onset ofmicroangiopathic hemolytic anemia, thrombo-
cytopenia, and renal dysfunction. DA-HUS is the most common form of the disease [1].
It usually follows adiarrheal prodrome and may be accompanied by central nervous sys-
tem complications including seizures and coma [1, 2]. Over the past severl decades, the
recognition and diagnosis as well as true incidence of DA-HUS has increased, and this
entity is currently considered to be the most common cause of acute renal failure in
infants andchildren in developed countries [1, 3,4]. The short-term outcome is generally
excellent and appears to be fairly consistent among various institutions despite the use of
varying modes of therapy [3-17]. However, less is known about the long term prognosis
forpatients who appear torecovercompletely from the acuteepisode.
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This report describes the experience at YaleUniversity School ofMedicine where 23
children were treated for DA-HUS between 1974 and 1989. All patients studied had ini-
tally recovered spontaneously and completely from the acute episode of DA-HUS from
1-15 years previously and had received only conservative, supportive therapy. Renal
duplex Doppler sonographic techniques, as well as standard laboratory and clinical mea-
surements, allowed for a non-invasive assessment of renal status. Doppler sonograms
were used to derive the resistive index (RI), a measure of renovascular resistance. The
RIs of the study group were compared to those of a group of normal patients of similar
ages. The goals of this study were a) to define the long term outcome for children who
were treated conservatively for DA-HUS, and who appeared to have a complete recovery
from the initial acute episode, b) to evaluate long-term complications which occur in this
group ofpatients who were treated conservatively relative to otherpatients who received
investigational therapies, and c) to determine ifany residual changes in renal blood flow
werepresent in these patients.
METHODS
This study was approved by the Human Investigations Committee ofYaleUniversity
School ofMedicine.
Patients. Computerized listings of the discharge diagnoses from the Pediatric
Services ofYale-New Haven Hospital, the Hospital ofSt. Raphael (New Haven, CT), and
Bridgeport Hospital (Bridgeport, CT) between January 1, 1974 and December 31, 1989,
were reviewed to determine those patients with a diagnosis of hemolytic uremic syn-
drome. The following data were recorded from the medical records of these patients:
demographic information and presenting symptoms; laboratory data on admission BUN,
serum creatinine, hemoglobin, hematocrit, platelet count, and serum sodium, potassium
bicarbonate, and chloride, and blood pressure on admission; maximum BUN, creatinine,
and blood pressure values during the hospital stay; minimum hemoglobin, hematocrit,
and platelet levels during hospitalization; the most abnormal urinalysis obtained during
admission; the adventofoliguria (urine ouput < 0.5 ml/kg/hr), length ofoliguria, the need
for dialysis, and length of dialysis, if performed; the need for transfusions and the type
and amountoftransfusions, ifgiven; theoccurrence ofseizures, complications during the
hospital stay, outcome, and length ofhospital stay; and the results of the most recent fol-
low-up evaluation available including blood pressure, urinalysis, BUN, serum creatinine,
hemoglobin, hematocrit, platelet count, height, weight, and length offollow-up.
Patients who met the following criteria were eligible for this study: 1) Patients were
less than 18 yr of age when diagnosed with hemolytic uremic syndrome, defimed by the
triad of microangiopathic hemolytic anemia (hematocrit < 30% and schistocytes on
peripheral smear), thrombocytopenia (platelet count < 150,000/mm3), and renal dysfunc-
tion (BUN > 18 mg/dl and a serum creatinine concentration > 1.2 mg/dl). 2) No evidence
ofrecurrent or familial pattern ofHUS. 3) Treatment with conservative, supportive man-
agement only, incuding dialysis and blood transfusions as necessary, but not with anti-
thrombotic, antiplatelet, or fibrinolytic agents or with fresh frozen plasma, intravenous
immunoglobulin, or plasmapheresis. 4) Apparent complete recovery from the acute ill-
ness as determined by hematocrit, platelet count, urine output, BUN, serum creatinine,
and blood pressure. 5) Follow-up of one year or more after recovery from the acute
episode.
Follow-up evalution. Subjects or their parents were mailed consent forms and letters
explaining theprojectand were then contacted by telephone and asked to come to YNHH
for follow-up studies. Follow-up evaluation included a medical history, physical exami-
nation, two blood pressure measurements always taken separately by the same two exam-
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iners (J. O'B., S.V.W.) and measurements of height and weight. Blood was drawn and
sent to the YNHH clinical laboratories for measurement of hemoglobin, hematocrit,
platelet count, BUN, and serum creatinine concentrations. Analysis of fresh urine was
performed using a dipstick (Labstix) to detect protein, glucose, ketones, or occult blood,
and with examination ofmicroscopic urine sediment by the same two observers (J. O'B.,
S.V.W.). Renal morphologic and duplex Doppler sonographic examinations were carried
out by the same examiner (M.K.) who was unaware of patient's clinical status, using
Mark 600 (Advanced Technology Laboratories, Bothell, WA) and Acuson 128 (Mountain
View, CA) units.
The three patients who no longer lived in Connecticut were asked to submit the
results of physical examinations, blood tests, and urinalyses performed by their private
physicians. It was notpossible to obtain renal sonograms ofthese subjects.
The following findings were consideredabnormal: 1) systolic ordiastolic blood pres-
sures > 90thpercentile forageand sexbasedon values oftheReportoftheTaskForceon
Blood Pressure Control in Children [18]; 2) heights or weights < 10th percentile for age
and sex based on growth curves from the National Center for Health Statistics; 3) serum
creatinine concentrations > 1.0 mg/dl; 4) glomerular filtration rates < 80 ml/min/1.73 m2
as determined by the formula defined by Schwartz et al. [19]; 5) BUN concentrations >
20 mg/dl; 6) hemoglobin and hematocrit values less than standard values for age and sex
[20]; 7) platelet counts < 150,000/mm3; 8) urine protein levels > 30 mg/dL (1+ or greater
detected by a dipstick); or9) the presence ofany casts, more than five leukocytes or more
than fiveerythrocytes perhigh powered field in centrifuged urine sediment.
Sonographic examinations of renal morphology included determinations of kidney
size, the presence or absence or renal scarring, abnormalities in the collecting system,
such as calyceal or renal pelvic dilatation, and cortical-medullary differentiation. Kidney
length was plotted against age, weight, height, and body surface area and compared to
values fornormal children [21]. Lengths above the 95th orbelow the 5th percentiles were
considered abnormal. Doppler sonographic studies included determination oftheresistive
index at the level of the segmental renal arteries and examination for the presence of a
patentmain renal vein. The RI orPourcelotindex isdefined as:
[peak systolic velocity - end diastolic velocity]
peak systolic velocity
The RI represents a quantitative assessment of the blood flow pattern through the vascu-
lature and provides an assessment of renovascular resistance [22]. With increased resis-
tance to flow, the RI increases because the wave form is more steep with increased sys-
tolic velocity and decreased diastolic velocity. This formula has been shown by Patriquin
etal. to predict the severity ofrenal microangiopathy, vascular resistance, and the resolu-
tion of oliguria and anuria during the acute phase of hemolytic uremic syndrome [23].
These values were compared with those of a randomly chosen control group of 30 chil-
dren (60 kidneys) of similar ages to the study subjects with no known renal or cardiac
disease.
Statistical analysis. The acute phase variables ofthe subjects in the study group and
of the patients lost to follow-up were compared using the Chi-square test with the Yates
continuity correction, Fisher's exact test, or the two-tailed Student t-test, as appropriate,
with a p value of < .05 considered significant. Comparison of the resistive indices of the
DA-HUS group with those of the control group was done using a z-test. Relationships
between continous variables were determined using the Pearson product-moment correla-
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tion coefficient, linear regression analysis, the general linear model to determine P for
each slope, andanalysis ofcovariance. In all cases, p < .05 was considered significant.
RESULTS
Patient data. Forty-seven patients were initally identified as having been admitted
with HUS to one ofthe three hospitals between January 1, 1974 and December 31, 1989.
Overall, six (12.8%) ofthe 47 HUS patients never recovered normal renal function: four
(8.5%) developed end-stage renal disease (ESRD) and two (4.3%) died during the acute
phase. Ofthese six patients with pooracute outcome, three did notexperience a diarrheal
prodrome.
There were 41 patients with spontaneous recovery from the acute episode. One of
these patients had experienced an episode of HUS associated with total body irradiation
received in preparation for a bone marrow transplant and was not included in this study.
Onepatient had a recurrence 15 mo afterthe initial episode. Oftheremaining 39 patients
with DA-HUS, 10 could notbelocated, butall had spontaneously recovered normal renal
function by the time of discharge and maintained normal renal function for as long as
they were followed (median follow-up period 1 mo., range0 to 22 mo.). Twenty-three of
the remaining 29 patients with DA-HUS agreed to participate in this study. The six
patients who declined to participate were in good health with no known deterioration of
renal function 1 to 16 yr. (median4 yr.) afterdischarge.
Comparison of acute phase features of the patients in the study group with those of
the sixteen patients lost to follow-up (10 not found and 6 refused to participate) revealed
the following significant differences: oliguria was more frequent in the study group (68%
vs 24%; p <0.02), and peritoneal dialysis was required more often in the study group
(55.5% vs 18%; p < .05). These differences suggest that the subjects in the study group
may have actually experienced more severe episodes of HUS than did those lost to fol-
low-up.
There were 15 females and 8 males in the final study group. All subjects were
Caucasian, all had experienced DA-HUS and the mean age of admission to the hospital
during the acute illness was 4.1 ± 2.8 yr. (median - 3.5 yr.; range - 6 weeks to 12 yr.).
Laboratory values upon admission to the hospital showed that renal function studies,
hematocrit, and platelet count were already markedly abnormal. The admission elec-
trolyte values were generally within normal limits except for bicarbonate values which
were low. Bloodpressure was within normal limits forall patients.
Laboratory values, which define HUS, demonstrated progression of the illness after
admission, with overall worsening of renal function (median BUN rose from 71 to 100
mg/dl; median creatinine rose from 2.8 to 3.9 mg/dl), anemia (median hemoglobin fell
from 7.7 to 6.1 g/dl; median hematocrit fell from 22.9 to 17.9%), and thrombocytopenia
(median platelet count fell from 67,000/mm3 to 45,000/mm3). Median systolic and dias-
tolic blood pressures also rose by 29 and 14 mm Hg, respectively. Thus, patients were
admitted to the hospital with laboratory values which were compatible with a diagnosis
ofHUS and theirdiseasereached apeak during the hospital stay.
Fifteen patients (68%) were oliguric and twelve (55%) subsequently required peri-
toneal dialysis. These patients were dialyzed for an average of 9 ± 6 d. (median 7.5 d.,
range 2 ± 21 d.). Ten patients (45%) received blood transfusions. No patients received
platelet transfusions. Five patients (23%) experienced seizures. The mean length of hos-
pital stay was 13 ±9 d. with a range from 3 to 33 d. (median 11 d.). There was no rela-
tionship between any ofthe acutephase variables(see Methods) andfinal outcome.
Follow-upData (Table 1). The mean length offollow-up was 6 yr. with arange from 1 to
15 years. All 23 patients had reportedly been in good health since recovering from their
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Table 1. Folow-up data.
Pt. # An Sx F/U BE U/A BUN Cr GFR Hct Hb Platelets
(yrs) (yrs) (mmHg) (mg/dl) (mg/dl) (cc/min/1.73m2) (%) (g/dl) (xlOOO)
1 7 F 1.8 88/58 nl 12 0.6
2 5 F 1.8 104/64 nl 13 0.4
3 15 F 12.8 104/70 ni 12 0.9
4 21 F 8.8 130/80 nl 13 0.8
5 4 F 1.5 102/58 nl 6 0.5
6 13 M 12.7 106/64 nl 19 0.7
7 1 1 M 9.2 92/56 nl 17 0.6
8 5 F 1.0 84/56 ni 17 0.7
9 6 M 1.0 90/60 nl 9 0.4
10 7 F 3.2 90/56 nl 15 0.5
11 10 M 7.25 92/60 nl 16 0.6
12 15 F 9.1 112/66 nl 11 0.7
13 12 F 8.2 92/60 nl 13 0.5
14 12 F 9.3 108/64 nl 16 0.6
15 12 F 7.2 100/58 nl 11 0.8
16 14 M 11.7 114/72 nl 13 0.7
17 7 F 3.3 90/58 nl 15 0.6
18 13 F 6.8 90/70 nl 18 0.7
19 22 M 15.3 120/80 nl 10 1.1
20 5 F 1.4 96/70 nl 19 0.4
21 3 F 1.4 106/75 1+pr 32 0.5
22 5 M 1.0 82/54 nl 17 0.4
23 13 M 1.5 86/60 nl 14 0.6
Mean(SD) 10(5) 6.0(4.6) 992L2) 15(5) 0.6(0.2)
64(8)
Median 11 6.8 96/60 14 0.6
Range 3- 1.0- 82- 6- 0.4-
22 15.3 130 32 1.1
111.1 38.8 12.8
137.5 a33.6 11.4
101.1 836.8 12.4
108.5 37.1 12.1
126.3 37.2 12.2
149.5 41.5 13.7
130.4 41.6 13.7
82.5 36.5 11.7
164.2 36.4 12.6
142.0 38.9 13.1
118.5 42.5 13.9
124.6 38.6 13.0
160.9
128.8 41.4 13.9
101.3 36.7 12.9
183.8 38.8 12.9
120.4 833.1 11.2
126.5 35.7 12.0
110.5 44.4 15.6
140.9 35.6 12.2
98.8 35.6 12.2
139.2 37.8 12.3
137.3 35.9 12.8
240
227
272
219
398
350
226
290
301
415
318
306
324
253
179
316
320
270
383
383
458
220
128.0(23.5) 37.9(2.9) 12.8(1.0) 307(73)
126.5 37.2 12.7 304
82.5- 33.1- 11.2- 179-
183.8 44.4 15.6 458
F/U=length of follow-up; BP=blood pressure; s=systolic; d=diastolic; U/A=urinalysis; Cr=serum creatinine; Hct-
hematocrit; Hb=hemoglobin
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acute episodeofDA-HUS.
All patients were at or above the 10th percentile for height and weight for their age
and sex. All patients (from whom previous height and weight data were available) had
maintained their appropriate growth curves. No systolic ordiastolic bloodpressures were
above the 80th percentile for age and sex. All patients had normal physical examinations
including fundoscopic, heart, lung, abdominal,extremity, andneurologicexaminations.
All hematological data were normal except for 3 hematocrit values within 1% ofthe
lower limit of normal. Urinalysis and renal function studies were normal in 22 of 23
patients (Table 1): mean serum creatinine concentration was 0.6 ± 0.2 mg/dl (range 0.4 -
1.1 mg/dl); BUN, 15 ± 5 mg/dl (range 6 - 32 mg/dl); and creatinine clearance, (128.0 +
23.5 ml/min/1.73m2). Onepatient (#21) had an abnormal urinalysis (1+ protein and a sin-
gle granular cast), an elevated urine protein: creatinine ratio of0.53 (normal < .20), and a
BUN of32 mg/dl. Hercalculated GFR was 98.8 mL/min/1.73m2.
UltrasoundData (Table 2). Evaluation of40 kidneys from 20 subjects (patients #15,
#16, and#23 were notavailable to study) usingrenal sonography to measure longitudinal
kidney length showed nokidneys to be smaller than the 5th percentiles forage, height, or
weight. The length of the left kidney ofsubject#10 was at the 95th percentile for weight
only. The length ofthe left kidney ofpatient #12 was greater than the 95th percentile for
height only. The length of the right kidney ofpatient #17 was greater than the 95th per-
centile for age, height, and weight. In each case (#10, #12, #17), the contralateral kidney
was within 1 cm ofthe largerkidney; thus, theincreased sizeofthe largerkidney was not
Table 2. Longitudinal kidney lengths measured bysonography.
1 7 F 121.2 24 8.1 8.3
2 5 F 100.0 17 7.1 7.1
3 15 F 165A 54 10.0 11.0
4 21 F 157.8 69 12.2 12.1
6 13 M 114.8 22 7.6 7.9
7 11 M 142.2 37 8.9 9.2
8 5 F 105.0 18 8.5 8.5
9 6 M 119.4 22 8.2 8.9
10 7 F 129.1 21 7.9 8.9
11 10 M 129.3 31 9.0 8.2
12 15 F 158.6 56 10.6 b11.5
13 12 F 146.0 39 9.4 10.3
14 12 F 140.0 33 9.1 9.3
17 7 F 131.0 31 >10.1 9.0
18 13 F 161.0 40 10.3 10.7
19 22 M 173.6 87 11.0 11.6
20 5 F 102.5 17 7.7 7.2
21 3 F 89.7 14 6.8 7.2
22 5 M 101.2 17 7.2 7.6
Mean 10(5) 8.9(1.A) 9.2(15)
Median 8.5 9.0 9.1
Range 3-22 6.8-12.2 7.1-12.1
R.K. = Right Kidney; LK. = left kidney
aLength = 95th percentile for weight only
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compensatory growth because of a small opposite kidney. There were no signs of renal
scarring, collecting system abnormalities, or abnormal cortical-medullary differentiation
seen on any ofthe sonograms. There were no scarred, shrunken or small kidneys.
Doppler sonography was used to derive RIs ofthe vascular flow pattern and to com-
pare the renovascular resistance in the DA-HUS subjects (40post-HUS kidneys) to those
of 30 randomly selected control subjects (60 normal kidneys). At the time of Doppler
examination, median ageofDA-HUS was 8.1 yr. (range 3-22yr.) and median ageofcon-
trol group was 8.2 yr. (range 0-16 yr.). The mean RIs ofthe DA-HUS and control groups
were not significantly different (.66 ± .05 and .67 ± .07, respectively). Both groups
showed a statistically significant decrease in RI with increasing age (DA-HUS: r2 = .121,
p = .0277; control: r2 = .492, p < .0001; Figure 1). However, using covariance analysis,
the DA-HUS patients demonstrated less ofa decrease in RI with age than did the control
group (p < .0002). Thus, for the DA-HUS patients, RI values overall were higher than
expected for a given age. The RIs of these patients were not studied longitudinally, the
patients had their acute illness at different ages and have had various lengths of follow-
up. Therefore, it is difficult to determine for certain the trend ofindividual RIs over time
and whether the rate ofRI decrease slowed, stopped falling completely, or even began to
rise after the initial episode ofDA-HUS. However, in the DA-HUS patients, agecorrelat-
ed with length of time since hospitalization (r2 = .78, p < .0001). Furthermore, when RI
was compared to length of follow-up, RI was found to fall slightly but significantly as
length of time since the acute illness increased (r2 = .248, p = .0011; Figure 2). Taken
together, these data suggest that renal vascular resistance in this group of children who
recovered from DA-HUS was decreasing over time as it does in normal children,
although atasignificantly slowerrate than wasobserved in thecontrol group.
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Figure 1. Correlations between resistive Indices and age of20 HUS subjects and 30 controls.
Closed arrow - HUS (n = 40 kidneys): y = .70-.003x, r2= .121, p = 0.0277; open arrow - control (n
=60 kidneys): y = .75-.Ollx, r2 = .492, p < .0001O'Brienetal.: Renovascular resistanceafterhemolytic uremicsyndrome
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Figure 2. Correlation between resistive indices and length of follow-up In 20 HUS patients
(n = 40 kidneys): y = 0.70-0.006x, r2 =.248, p =.0011.
DISCUSSION
There have been many reports which describe the immediate outcome ofchildhood
DA-HUS (Table 3). Overall, acute mortality has improved dramatically over the past 20
yr. This has been attributed, in part, to increasing recognition ofmilder cases ofHUS as
well as to improved supportive management. Gianantonio, who has reported the largest
number ofHUS patients, noted that over 15 years the acute mortality rate dropped from
47% to 6.25% with increasing use ofperitoneal dialysis [2]. The question of whether or
not to pursue moreaggressive therapy has beencontroversial.
Damage to endothelial cells caused by an E.coli 0157:H7 Vero cell cytotoxin (VT1
or SLT-I) is currently considered the primary pathogenic mechanism of classic HUS [1,
30-33]. The fibrin depositions associated with TMA have led investigators to suggest
additional mechanisms including activation ofintravascular coagulation cascade, platelet
activation, and prostacyclin deficiency [2, 34, 35]. Therefore, therapeutic interventions
with anti-thrombotic agents such as anti-coagulants, platelet inhibiting agents, and fibri-
nolytic agents to minimize the extent and effects ofTMA have been tried [6, 27, 36, 37].
There have also been trials of plasmapheresis and infusions of fresh frozen plasma,
prostacyclin, and immunoglobulin attempting to correct the proposed deficiencies in
prostacyclin synthesis and other abnormal factors found in the sera ofHUS patients [14,
15, 38-40]. None of these therapies has been shown to improve definitively or signifl-
cantly the acute outcome ofDA-HUS.
8O'Brienetal.: Renovascularresistanceafterhemolytic uremicsyndrome
Table 3. Data on short-term outcome ofInfants and children with HUS: Review ofliterature.
No. of ots. Theravy(*) Died(%) ESRD&Recovered(%)
heparin(8) 34.3
heparin 33.0
heparin(26) 11.0
heparin 40
none 30
heparin 36
none 41
multiple 25
heparin 16.8
none 20.6
? 16
heparin(I) 15
none 4.5
heparin 5.7
streptokinase 7.9
heparin 25
none 0
none 2
? 17
heparin 6.6
heparin(45) 7
variable 4
variable 7
FFP 5
none 5
FFP 0
none 0
? 5.6
? 3.4
? 3.4
Salt Lake City, 118
29 36
23 36
0 75
--_
10 75
9 89
12.5 71
4.4 86.7
15.7 77
23.6 69.4
5 90
5 90
0 100
0 100
5.6 89
14 82
2.5 _ _
1991[17] Utah
9
Authorfrefl
Kaplan et al.
1971[24]
Gianantonio
et al.1973(2]
Vitacco et al.
1973(25]
Powell et al.
1974[26]
Proesmans
et al.1974[27]
van Wieringen
et al. 1974[28]
Janssen et al.
1974[29]
Kaplan et al.
1976[5]
Monnens et al.
1978(6]
Sorrenti et al.
1978(7]
Dolislager et al.
1978(8]
Donckerwolcke
et al. 1979(9]
Binda Ki Muaka
et al.1981[10]
Habib et al.
1982(11]
Trompeter et al.
1983(12]
Loirat et al.
1984[13]
Loirat et al.
1988(14]
Rizzoini et al.
1988[15]
van Dyke et al.
1988[16]
Tarr et al.
1989[3]
Martin et al.
1990(4]
Siegler et al.
Location
Johannesburg,
South Africa
Buenos Aires
Buenos Aires
Melbourne,
Australia
Leuven,
Belgium
Netherlands
Brussels
Johannesburg,
South Africa
Netherlands
Chicago
(IL & IN)
Stanford, CA
Utrecht
Leuven,
Belgium
Paris
London
Paris
Paris
Italy
Leuven,
Belgium
King County,
Washington
Minnesota
67
39(lit.rev.)
678
10
20
14
22
8
191
1012
212
20
44
35
38
4
15
45
72
45
70
72
67
39
40
17
15
54
59
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Overall mortality (4.3%) and morbidity (8.5% ESRD) rates for the present series
during the acute stage of the illness are comparable to those previously reported (Table
3). The mortality and morbidity ofthe present series ofpatients with DA-HUS who were
managed conservatively are compatible with other series which include experimental
therapeutic interventions. Moreover, since an entry criterion ofthis study was an apparent
spontaneous resolution ofthe acute episode ofDA-HUS, it is important to note that fol-
low-updataare notbiased by high acute morbidity ormortality.
Published observations oflong term follow-up status ofchildren with HUS are high-
ly variable (Tables 3 and4). Overthepast20 yr., long-term follow-upstudies have shown
theproportion ofpatients withoutany sequelae to range from 60-97% (excluding thepar-
ticularly severe cases reported from Argentina). Proportions of patients with residual
hypertension (0-20%), proteinuria (0-32%), low creatinine clearances (0-57%), and
chronic renal failure (0-11%) have also been inconsistent. Interpretation of these large
variations in outcome is difficult. Most long-term follow-up studies describe collectively
all HUS patients, some or all of whom were often acutely treated with multiple and dif-
fering therapeutic approaches and some of whom did not have a diarrheal prodrome.
Occasionally, there is no mention ofhow patients were treated during the acute episode.
The putative effects ofexperimental therapies, administered during the acute episode, on
long-term outcome are not known. Various experimental interventions could have had
significant effects on later outcome that were not, initially, appreciated or anticipated.
Many long-term follow-up studies also do not distinguish a recovery group from those
who neverregainedrenal function whenreporting ratesoflong term sequelae.
Another issue confounding the data on later sequelae ofchildhood HUS is the diffi-
culty of detecting early renal insufficiency non-invasively. Standard measurements of
renal function (serum creatinine and BUN) may not become detectably abnormal until
renal failure is fairly advanced. ORegan et al. found no correlation between abnormal
GFR measured by9*,TcDTPA plasma slopeclearance andnormal BUN andplasma crea-
tinine concentrations in follow-up ofpatients with HUS [41] which raises the possibility
that somepost-HUS patients withresidual chronic renal insufficiency arebeing missed.
This follow-up study of HUS patients differs from many previous similar studies in
that all subjects had DA-HUS and were treated conservatively during the acute illness.
Thus, the problem of various, confounding acute therapies which might complicate the
natural history of recovery from HUS is eliminated. Also, this follow-up study focussed
exclusively on those patients who recovered completely from the initial episode. Finally,
in addition to routine follow-up testing, this study incorporated measurements of creati-
nine clearance as well as sonographically determined kidney size, appearance, and reno-
vascular resistance as indications ofresidual renal injury.
Comparison offeatures during the acute phase indicated that those lost to follow-up
(16 of 39 eligible patients) may have experienced a less severe course than did those in
the study. This suggested that the observed outcomes in the study group were not biased
because ofamild initial phase ofHUS. Thus, it seems unlikely thatthe parameters exam-
ined underestimated the rates oflatersequelae forthe entire group.
Calculated GFRs which are based on serum creatinine concentrations may overesti-
mated true renal function [41, 42]. Thus, subtle decreases in GFR may have been unde-
tected. However, the outcome measures used in this study were those most commonly
available, and the estimation ofGFR by the Schwartz formula has been shown to corre-
late closely with inulin clearance [19]. If substantial declines in GFR were present, one
would have anticipated that abnormalities in kidney size, composition, or shape would
also havebeen presentand theselatteralterations were notdetected.
By routine criteria, including GFR calculations, none of the patients in this study
loO'Brien etal.: Renovascular resistanceafterhemolytic uremicsyndrome
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demonstrated any significant sequelae, thus appearing to exhibitmore favorable outcomes
than have patients reported elsewhere [2, 11, 13, 16, 17]. One patient had minor urine
abnormalities noted on one examination. Furthermore, all kidneys measured were ofnor-
mal size, and no evidence ofrenal parenchymal scarring was seen by sonographic evalua-
tion. These results are most similar to those reported by Janssen [29], Kaplan [5], and
Dolislager [8], who described a combined total of92 HUS patients from Belgium, South
Africa, and California, respectively. All ofthesepatients were treated conservatively dur-
ing the acute episode, and in each group90% werewithoutany sequelaeatfollow-up.
Other follow-up series have shown less successful outcomes (Table 4). Of note, the
pooreroutcome hasbeenreported morefrequently in studies in which experimental thera-
py was used during the acute episode or therapeutic intervention is not delineated. While
it could be argued that more severely ill patients are selected for experimental therapies,
the acutephase variables assessed in this study suggestthattheincidence ofoliguria, dial-
ysis therapy, or seizures in our group ofpatients were similar to thosereported by others.
Thus, the poorer outcome reported in other studies is not necessarily from inclusion of
patients who were moreacutely ill compared to thosereported in this study. Alternatively,
it is possible that higher rates of sequelae seen in other studies resulted from latent side
effects of various investigational therapies used during the acute episode. For example,
Binda Ki Muaka et al. initially found complete recovery in 38 of 39 patients who had
been treated with heparin and dipyridamole during the acute episode [10]. However, a re-
evaluation of this same group ofpatients, by Van Dyck et al., found only 70% normal at
10 yr. follow-up [16]. Similarly, in a 5 - 21 yr. follow-up of 103 children with DA-HUS,
Fitzpatrick et al. reported that 31% had microalbuminuria, 18% had reduced GFR, and
10% had both in association with higher systolic blood pressure [11]. Unfortunately, ther-
apeutic interventions, during the acute phase ofthe illness, are notdelineated in this latter
study [11]. While our findings are not definitive, an intense and thorough evaluation of
this possibility should be undertaken in those centers which have employed investigation-
al therapies.
The only abnormality found among the patients in the present series was a signifi-
cantly slower age-related decrease in renovascular resistance determined by Doppler
ultrasound examination ofthe segmental renal arteries. This statistically significant differ-
ence in resistive index between DA-HUS and normal subjects did not appear to represent
a clinically relevant difference, at least for up to 15 yr. after the acute episode. The
increase in renal vascular resistance and diminished rate ofdecline in RI in HUS patients
may reflect the irreversible injury to some glomeruli or microvascular beds during the
acute episode. Whether or not the DA-HUS patients will eventually achieve normal RI
values is unclear from the present data. Longer follow-up would be necessary to deter-
mine whether the RIs of these DA-HUS patients continue to fall until they reach normal
levels, or whether after a certain age renal vascular resistance will plateau at a higher lev-
el and represent a harbinger of later sequelae, possibly in adulthood. This possibility
would be compatible both with the poorer outcome reported by Fitzpatrick [11], whose
patients were studied later in follow-up than ours, and with the observation by Siegler et
al. thatabnormalities appeared in some cases after an interval ofapparent recovery [171.
In conclusion, this study indicates that patients who have recovered from DA-HUS
with only conservative management have an excellent prognosis and provides supportive
evidence for the efficacy and safety of conservative management of the acute phase of
DA-HUS. However, the clinical implications of increased renovascular resistance, with-
out other clinical sequelae, remain to be determined.
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